FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Rare Disease Drug Development Guidance

FDA publishes a guidance to assist sponsors in conducting efficient and successful drug development programs to treat rare diseases.

latest-news-card-1
Human Drugs

Drug Development Master Protocol Guidance

FDA publishes a draft guidance making recommendations on the design and analysis of drug development trials conducted under a master protocol.

latest-news-card-1
Human Drugs

Updated Labeling for Promethazine HCl

FDA requires updated labeling for promethazine HCl injection to recommend administration through deep intramuscular rather than intravenous administra...

latest-news-card-1
Biologics

Cell/Gene Product Potency Assurance

FDA publishes a draft guidance on developing a science- and risk-based strategy to help assure the potency of a human cellular therapy or gene therapy...

latest-news-card-1
Human Drugs

CGMP Violations at Patco Cosmetics

FDA warns Indias Patco Cosmetics about CGMP violations in its manufacturing of finished over-the-counter drugs.

latest-news-card-1
Human Drugs

Dont Use Counterfeit Ozempic: FDA

FDA says it has seized thousands of units of counterfeit Ozempic that also contain counterfeit needles.

latest-news-card-1
Human Drugs

Califf Discusses More Clinical Research Options

FDA commissioner Robert Califf says a new final rule allowing some waivers of informed consent will enable minimal-risk research that would not otherw...

latest-news-card-1
Human Drugs

Topical Ophthalmic Quality Guidance

FDA publishes a draft guidance revising a recent draft on quality considerations for topical ophthalmic drugs.

latest-news-card-1
Human Drugs

CGMP Violations in Omeza Inspection

FDA warns Sarasota, FL-based Omeza about CGMP violations in its production of unapproved and misbranded over-the-counter drugs.

latest-news-card-1
Human Drugs

2nd CRL for Mercks Gefapixant Chronic Cough Drug

FDA issues a complete response letter for the Merck resubmitted NDA for gefapixant, saying the drug did not establish substantial evidence of efficacy...